Back to Awarded Treatment Trials
Awarded Trial: 01T-426
Grant ID
01T-426
Illness
Schizophrenia
Primary Drug/Intervention
AIT-082
Primary Dosage
1000 mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Fleming
Sample Size
20
Duration of Study Period for Each Subject
16 weeks
Outcome Measurements
Cognitive battery
Results
AIT-082, a hypoxanthine derivative thought to improve neurotrophic factor function, showed no beneficial effects on symptom ratings or on cognitive measures for patients with schizophrenia.
Publication
N/A
Link
N/A
PI Name
Kirsten Fleming
Degree
MD
Center
Department of Psychiatry and Human Behavior
Institution
University of California, Irvine
Address
Bldg. 3 - Rt 88
City or Town
Irvine
State or Province
CA
Zip or Postal Code
92697
Country
USA
Email Address
k.fleming@uci.edu